Trade OpGen, Inc. - OPGN CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | N/A |
Open | 2.27 |
1-Year Change | 453.66% |
Day's Range | 1.88 - 2.73 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Aug 19, 2024 | 1.93 | -0.33 | -14.60% | 2.26 | 2.83 | 1.85 |
Aug 16, 2024 | 2.28 | 0.05 | 2.24% | 2.23 | 2.29 | 2.22 |
Aug 15, 2024 | 2.23 | 0.04 | 1.83% | 2.19 | 2.24 | 2.19 |
Aug 14, 2024 | 2.20 | 0.01 | 0.46% | 2.19 | 2.27 | 2.11 |
Aug 13, 2024 | 2.08 | -0.15 | -6.73% | 2.23 | 2.23 | 2.05 |
Aug 12, 2024 | 2.09 | -0.11 | -5.00% | 2.20 | 2.20 | 2.05 |
Aug 9, 2024 | 2.22 | 0.00 | 0.00% | 2.22 | 2.22 | 2.21 |
Aug 8, 2024 | 2.27 | 0.04 | 1.79% | 2.23 | 2.27 | 2.23 |
Aug 7, 2024 | 2.28 | 0.04 | 1.79% | 2.24 | 2.32 | 2.16 |
Aug 6, 2024 | 2.24 | -0.09 | -3.86% | 2.33 | 2.50 | 2.24 |
Aug 5, 2024 | 2.48 | -0.10 | -3.88% | 2.58 | 2.61 | 2.16 |
Aug 2, 2024 | 2.72 | -0.11 | -3.89% | 2.83 | 2.87 | 2.71 |
Aug 1, 2024 | 2.93 | 0.00 | 0.00% | 2.93 | 2.96 | 2.86 |
Jul 31, 2024 | 2.87 | -0.04 | -1.37% | 2.91 | 2.94 | 2.85 |
Jul 30, 2024 | 2.94 | -0.02 | -0.68% | 2.96 | 3.00 | 2.94 |
Jul 29, 2024 | 2.98 | -0.06 | -1.97% | 3.04 | 3.04 | 2.96 |
Jul 26, 2024 | 2.99 | 0.03 | 1.01% | 2.96 | 3.02 | 2.96 |
Jul 25, 2024 | 2.97 | 0.01 | 0.34% | 2.96 | 3.04 | 2.96 |
Jul 24, 2024 | 2.96 | 0.02 | 0.68% | 2.94 | 2.96 | 2.94 |
Jul 23, 2024 | 2.98 | -0.02 | -0.67% | 3.00 | 3.00 | 2.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
OpGen, Inc. Company profile
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company''s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.Industry: | Biotechnology & Medical Research (NEC) |
9717 Key West Avenue
Suite 100
20850
News
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com